Half of the patients who received a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma remained alive and progression-free five years later without requiring additional treatment. This finding stems from the initial 20-patient subgroup of cohort A in the Phase 2 CARTITUDE-2 study, marking a significant durability milestone for a blood cancer traditionally defined by continuous relapse cycles.
Five-Year Progression-Free Survival Achieved in Early-Line Multiple Myeloma Patients Following Single Cilta-Cel Infusion
Regulatory Context and the CARTITUDE-2 Trial Design
The U.S. Food and Drug Administration expanded the approval of CARVYKTI (cilta-cel) in April 2024 to treat adults with at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. While the therapy was originally developed for heavily pretreated populations, the CARTITUDE-2 trial provides crucial durability data for this earlier-line patient group.
The trial operates as a multi-cohort, single-arm Phase 2 study rather than a randomized controlled trial. Cohort A initially enrolled 20 patients, a small sample size that requires careful interpretation since single-arm data can sometimes yield response rates that shift when evaluated at a larger scale. However, the trial’s extensive follow-up time offers a clear look at long-term outcomes that standard accumulated trial experience in this therapeutic class has not consistently demonstrated.
Documenting a five-year progression-free window after a single infusion shifts the primary objective of myeloma treatment from managing chronic relapse to achieving genuine treatment independence. Patients typically cycle through continuous maintenance regimens indefinitely, making a multi-year treatment-free interval a distinct clinical departure from standard care.
As larger randomized trials within the broader CARTITUDE clinical program reach maturity, researchers will monitor whether this five-year treatment-free fraction remains consistent across larger patient populations. Sustained durability data at this scale could further solidify the positioning of CAR-T therapies earlier in the treatment sequence.
Keep reading